The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

Several years of preliminary research results suggest chimeric antigen receptor (CAR) T-cell therapy could benefit pediatric patients with refractory systemic lupus erythematosus (SLE). When diagnosed ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

Please provide your email address to receive an email when new articles are posted on . Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus ...

In this retrospective analysis, responses persisted with hydroxychloroquine treatment. Results of a study suggest treatment using hydroxychloroquine (HCQ) for immune thrombocytopenia (ITP) related to ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

Seattle Children’s is the first FDA-authorized site to deliver an experimental CAR T-cell therapy to children with lupus, the system said March 11. About 20% of lupus patients have disease onset ...

The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and ...

The 200-mg subcutaneous injection is for children 5 years and older. HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta ...